Recent Publications
Harris N, et al 2014. Small Molecule Inhibitors of Protein Interactions with
Glycosaminoglycans (SMIGs), a Novel Class of Bioactive Agents with Anti-
Inflammatory Properties. Biochimical Biophysica Acta 1840, 245-254
Ezerzer C, Harris N, et al 2009. Chemokine receptor-derived peptides as
multi-target drug leads for the treatment of inflammatory diseases,
Peptides 30, 1296-1305
Ezerzer C, Harris N 2007. Physiological immunity or pathological
autoimmunity – A question of balance. Autoimmunity Reviews 6, 488-496
ORT Braude College
2013-14 – Molecular Biology (laboratory)
2006-2010 Co-Founder and VP R&D, Symthera (ProtAgonists) Ltd, Weizmann Science Park, Ness Ziona, Israel. Privately
owned biopharmaceutical startup established to discover and develop peptide drugs for the treatment of inflammatory diseases
2000-2005 Co-Founder and VP R&D, Rimonyx Pharmaceuticals Ltd, Weizmann Science Park, Ness Ziona, Israel. Privately owned biopharmaceutical startup established to discover and develop small molecule drugs for the treatment of inflammatory diseases
1999-2000 Laboratory Manager, Blood and Bone Marrow Transplant Unit, Tel-Aviv Medical Center, Tel-Aviv, Israel
1997-1999 Laboratory Manager, Laboratory of Molecular Biology, Department of Gastroenterology, Tel-Aviv Medical Center
1995-1997 Senior Scientist, QBI Enterprises Ltd, Weizmann Science Park, Ness Ziona, Israel. Privately owned biopharmaceutical startup established to develop drugs for the treatment of retinopathy, myocardial ischemia and acute renal failure, consequences of oxidative stress